EGFR-targeted therapeutics have been ineffective so far: the addition of the EGFR-targeted antibody cetuximab to chemotherapy failed to show any significant benefit in the phase III EXPAND trial (Lordick et al. 2013), the addition of the anti-EGFR antibody panitumumab to chemotherapy did not improve overall survival of patients in the phase III REAL3 trial (Waddell et al. 2013), and in the SWOG 0127 trial, the small-molecule inhibitor erlotinib did not improve the outcome of patients with metastatic or unresectable gastric cancer (Dragovich et al. 2006). Here, EGFR is linked to gastric cancer.